Paris

Carlos RONCERO

and as a psychologist from the UNED (Madrid). He did his doctorate in psychiatry at the Rovira i Virgily University of Tarragona. He is a psychiatrist specializing in drug dependence and dual diagnosis, as well as professor in the Department of Psychiatry and Forensic Medicine of the Universitat Autònoma de Barcelona (Spain) since 2005, where he teaches psychiatry in the position of Associate Lecturer. He has taught numerous courses and lectures for pre- and post-graduate university students, doctors in training, psychiatrists, psychologists and general practitioners in Europe, Latin America, the USA and Africa. He has also collaborated with international agencies, task forces, committees and societies such as the WPA, WFSBP, APAL, OEA and CELAD. 

Dr. Roncero works in the Psychiatry Department of the Hospital Universitari Vall d’Hebron in Barcelona (Spain), where he has been the Head of the Addiction and Dual Diagnosis Unit since 2015. His work includes a clinical position and a training residency and he is involved in research trials of new medications for drug-dependent/dual-diagnosis patients, as well as the study of the neurobiological and clinical markers of addition. 

He has received grants from ICIII and from PND for the study of the comorbidities and cocaine dependence, and was the principal investigator in clinical trials for treatment of alcohol dependence, cocaine dependence and schizophrenia. 

Dr. Roncero has authored 134 articles (in Spanish and English) and 79 book chapters, in addition to co-editing 10 books on the psychopharmacology of drug dependence, treatment of dual-bipolar/dual-schizophrenic patients, cannabis dependence, opiate dependence, personality disorders and schizophrenia. 

Since May 2002, he has been a board member of the Spanish Society of Dual Diagnosis (Sociedad Española de Patología Dual), becoming vice-secretary in May 2008. He has been a board member of the Dual Pathology /Dual disorders section of the World Psychiatric Association (WPA) since December 2012 and of the World Dual Diagnosis Association since